Dendritic cell (DC) vaccines can be considered as a promising immunotherapy approach for patients with malignant gliomas. The efficacy of DC vaccines is critical for patients with malignant gliomas.

Anaplastic thyroid cancer (ATC) has a median survival of less than 6 months from diagnosis. BRAF V600E mutation is present in 20–30% of ATCs. For patients with BRAF V600E mutation, BRAF-targeted therapy may downstage initially unresectable disease to facilitate surgical resection, leading to improved survival and improve survival for metastatic disease (compared with traditional treatments).

Lower- and middle-income countries are experiencing a concerning upward trend in breast cancer (BC) incidence, necessitating the implementation of cost-effective screening methods. Population-based randomized trials have gathered evidence for the role of clinical breast examination in significant down-staging of BC, which can be performed by trained health workers in minutes.

Seven progression-free survival (PFS) events were reported in the patients with anaplastic lymphoma kinase-positive lung squamous cell carcinoma, and the median PFS was not estimable.

NAFLD is an independent risk factor for biochemical recurrence in patients with high-grade metastatic prostate cancer .

Estimates of worse-case, typical and best-case scenarios provide more hope and meaning to patients starting systemic therapy for metastatic breast cancer. Simple multiples of the median overall survival from clinical trials can accurately estimate representative survival scenarios for patients commencing endocrine therapy for metastatic breast cancer

Both chemotherapy and immunotherapy are active against pleural mesothelioma in an unselected real-world cohort in Queensland, Australia. However, overall outcomes remain poor with a significant need to improve treatment options, especially in the first-line setting.

Early drug development of novel cancer therapeutics in Australia is increasing through phase 1 oncology trials Phase 1 trials across Australia have mostly utilized immunomodulatory and targeted approaches.

Donafenib combined with HAIC in the treatment of unresectable HCC patients can notably reduce serum AFP levels, improve hepatic fibrosis, enhance short-term efficacy, prolong progression-free survival, and have a favorable safety profile .

We conducted, in a Tunisian center, a retrospective study on 90 patients, revealing adherence to 2023 European Society for Medical Oncology recommendations for venous thromboembolism treatment in cancer patients. Guidelines were fully followed in only 54.4% of cases. Financial constraints experienced by patients were significantly associated with less compliance with guidelines.

E74-like factor 4 transcriptionally activates integrin subunit beta 8 antisense RNA 1 (ITGB8-AS1) and promotes the binding of ITGB8-AS1 to the enhancer of zeste homolog 2, which catalyzes the histone H3 lysine 27 trimethylation modification in the claudin-23 (CLDN23) promoter, thus decreasing CLDN23 expression and accelerating colorectal cancer progression.

The prediction model based on radiomics and genomics features has a good prediction performance for STAS

The tumor immune microenvironment of adenoid cystic carcinoma was the so-called immune desert type, which may explain the poor response of this type to immune checkpoint inhibitors. In contrast, high-grade mucoepidermoid carcinoma was of the immune inflamed type, which may support the application of immune checkpoint inhibitors to this pathological subtype.